Apnimed, Inc., a pharmaceutical company advancing an industry-leading pipeline of first-in-class oral therapies that address the root causes of obstructive sleep apnea (OSA) and other sleep-related ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the number of nightly breath-stopping events by 46.8%, hitting the test's ...